查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1876019

急性偏頭痛治療：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Acute Migraine Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 96 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球急性偏頭痛藥物市場規模估計為 24.2 億美元，預計到 2031 年將達到 39.36 億美元，2025 年至 2031 年的複合年成長率為 7.3%。

本報告對近期急性偏頭痛藥物的關稅調整和國際戰略應對措施進行了全面評估，包括其對跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組的影響。

偏頭痛是一種反覆發作、難以預測的頭痛疾病，發作期間會嚴重影響日常生活。它是最常見的神經系統疾病之一，對患者的生活品質造成顯著影響。偏頭痛是一種以發作為特徵的慢性疾病。發作時，患者會感到中度至重度、通常為單側的搏動性頭痛，每次發作通常持續4至72小時。

急性偏頭痛藥物市場的主要促進因素是全球偏頭痛盛行率的不斷上升，偏頭痛已被公認為全球主要致殘原因之一。根據全球疾病負擔研究，偏頭痛影響著全球超過10億人，尋求有效且快速起效的急性偏頭痛治療的患者人數也不斷增加。這推動了對非處方藥（OTC）和處方藥（SumatriptanRizatriptan；吉潘類藥物，如烏布羅吉潘、瑞美吉潘；以及拉斯米地坦）的需求。對偏頭痛病理生理學，特別是抑鈣素基因相關胜肽（CGRP）作用的深入了解，促成了新型標靶治療的研發，這些療法具有更高的療效和耐受性。此外，患者和醫療保健提供者對偏頭痛的認知不斷提高，神經科醫療服務的可近性不斷改善，以及遠端醫療平台的擴展，都有助於偏頭痛的診斷和及時干預。個人化醫療的日益普及，尤其是在高所得國家，進一步推動了基於患者獨特誘因、合併症和藥物耐受性的個人化急性偏頭痛治療方案的應用。製藥公司正積極投資於偏頭痛藥物的研發和生命週期管理，包括開發能夠快速緩解症狀並提高患者依從性的新型劑型，例如鼻噴劑、口溶錠（ODT）和注射劑。儘管治療選擇不斷增加，但急性偏頭痛藥物市場仍面臨許多挑戰，這些挑戰可能會限制其成長軌跡。其中最主要的挑戰之一是新型治療方法的高成本，特別是CGRP受體拮抗劑和地西泮類藥物。部分此類藥物可能並非所有患者都能負擔得起或獲得，尤其是在中低收入國家。保險覆蓋範圍和報銷限制進一步限制了患者的用藥途徑，迫使許多患者依賴療效較差的舊藥。此外，偏頭痛的漏診和誤診，尤其是在基層醫療機構，仍然是治療推廣的主要障礙。許多出現偏頭痛症狀的人並未就醫，在某些情況下，他們的病情會被誤診為其他疾病，例如鼻竇性頭痛或緊張型頭痛。此外，藥物過度使用性頭痛（MOH）的風險，特別是曲坦類藥物和非類固醇消炎劑藥（NSAIDs）的風險，需要謹慎的臨床管理，並限制了某些急性偏頭痛藥物的長期使用。來自非藥物療法（例如神經調節設備和行為療法）的競爭也使市場更加複雜。藥物核准和上市後監測方面的監管障礙，特別是對於新型治療方法，可能會延遲產品上市並增加研發成本。最後，儘管急性醫療照護模式正在不斷發展，但從神經科到全科醫生，偏頭痛診療服務的分散性導致治療模式不一致，並影響先進藥物的市場滲透率。克服這些挑戰需要在定價策略、醫療服務提供者教育以及改善診斷和專科護理的可近性方面做出共同努力。

本報告旨在按地區/國家、類型和適應症對全球急性偏頭痛藥物市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以銷售（千）和收入（百萬美元）為單位，對急性偏頭痛藥物市場規模、估計值和預測進行了呈現，基準年為2024年，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定急性偏頭痛藥物業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • GSK
  • Teva
  • Pfizer
  • Novartis
  • Sun Pharma
  • Grunenthal
  • Endo Pharmaceuticals
  • Merck
  • J & J

按類型分類的細分市場

  • 曲坦類藥物
  • 非類固醇消炎劑（NSAIDs）
  • 其他

應用領域

  • 醫院藥房
  • 藥局

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Acute Migraine Drugs was estimated to be worth US$ 2420 million in 2024 and is forecast to a readjusted size of US$ 3936 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Acute Migraine Drugs cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient's quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate-severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.

The primary driver of the acute migraine drugs market is the increasing global prevalence of migraine, which is recognized as one of the leading causes of disability worldwide. According to the Global Burden of Disease study, migraine affects over one billion people globally, with a growing number of patients seeking effective, fast-acting treatments for acute migraine attacks. This has fueled demand for both over-the-counter (OTC) analgesics and prescription medications such as triptans (e.g., sumatriptan, rizatriptan), gepants (e.g., ubrogepant, rimegepant), and ditans (e.g., lasmiditan). Advances in understanding migraine pathophysiology, especially the role of calcitonin gene-related peptide (CGRP), have led to the development of novel, targeted therapies that offer improved efficacy and tolerability. In addition, increasing awareness among patients and healthcare providers, better access to neurological care, and the expansion of telemedicine platforms have enhanced diagnosis and timely intervention. The rising focus on personalized medicine, particularly in high-income countries, is further encouraging the use of tailored acute migraine treatments based on patient-specific triggers, comorbidities, and drug tolerability. Pharmaceutical companies are actively investing in R&D and life-cycle management of migraine drugs, including the development of new delivery formats like nasal sprays, orally disintegrating tablets (ODTs), and injectables that provide rapid relief and better patient compliance.Despite the expanding therapeutic options, the acute migraine drugs market faces several challenges that could limit its growth trajectory. One significant issue is the high cost of newer therapies, particularly CGRP receptor antagonists and ditans, which may not be affordable or accessible to all patient populations, especially in low- and middle-income countries. Insurance coverage and reimbursement limitations further restrict patient access, leading many to rely on older, less effective medications. Additionally, underdiagnosis and misdiagnosis of migraine-especially in primary care settings-remain major barriers to treatment uptake. Many individuals with migraine symptoms do not seek medical help, and some are incorrectly treated for other conditions like sinus headache or tension-type headache. Furthermore, the risk of medication overuse headache (MOH), particularly with triptans and NSAIDs, requires careful clinical management, limiting long-term use of some acute migraine drugs. Competition from non-pharmacological treatments, such as neuromodulation devices and behavioral therapy, also adds complexity to the market. Regulatory hurdles in drug approval and post-market surveillance, especially for novel therapies, can delay product launches and increase development costs. Lastly, while the acute treatment landscape is evolving, the fragmented nature of migraine care delivery-ranging from neurologists to general practitioners-creates inconsistencies in treatment patterns, affecting market penetration of advanced drugs. Overcoming these challenges will require concerted efforts in pricing strategy, healthcare provider education, and improved access to diagnostics and specialist care.

This report aims to provide a comprehensive presentation of the global market for Acute Migraine Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Acute Migraine Drugs by region & country, by Type, and by Application.

The Acute Migraine Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Migraine Drugs.

Market Segmentation

By Company

  • GSK
  • Teva
  • Pfizer
  • Novartis
  • Sun Pharma
  • Grunenthal
  • Endo Pharmaceuticals
  • Merck
  • J & J

Segment by Type

  • Triptans
  • NSAIDs
  • Others

Segment by Application

  • Hospital Pharmacies
  • Drug Stores

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Acute Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Acute Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Acute Migraine Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Acute Migraine Drugs Product Introduction
  • 1.2 Global Acute Migraine Drugs Market Size Forecast
    • 1.2.1 Global Acute Migraine Drugs Sales Value (2020-2031)
    • 1.2.2 Global Acute Migraine Drugs Sales Volume (2020-2031)
    • 1.2.3 Global Acute Migraine Drugs Sales Price (2020-2031)
  • 1.3 Acute Migraine Drugs Market Trends & Drivers
    • 1.3.1 Acute Migraine Drugs Industry Trends
    • 1.3.2 Acute Migraine Drugs Market Drivers & Opportunity
    • 1.3.3 Acute Migraine Drugs Market Challenges
    • 1.3.4 Acute Migraine Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Acute Migraine Drugs Players Revenue Ranking (2024)
  • 2.2 Global Acute Migraine Drugs Revenue by Company (2020-2025)
  • 2.3 Global Acute Migraine Drugs Players Sales Volume Ranking (2024)
  • 2.4 Global Acute Migraine Drugs Sales Volume by Company Players (2020-2025)
  • 2.5 Global Acute Migraine Drugs Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Acute Migraine Drugs Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Acute Migraine Drugs Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Acute Migraine Drugs
  • 2.9 Acute Migraine Drugs Market Competitive Analysis
    • 2.9.1 Acute Migraine Drugs Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Acute Migraine Drugs Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Migraine Drugs as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Triptans
    • 3.1.2 NSAIDs
    • 3.1.3 Others
  • 3.2 Global Acute Migraine Drugs Sales Value by Type
    • 3.2.1 Global Acute Migraine Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Acute Migraine Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Acute Migraine Drugs Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Acute Migraine Drugs Sales Volume by Type
    • 3.3.1 Global Acute Migraine Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Acute Migraine Drugs Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Acute Migraine Drugs Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Acute Migraine Drugs Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital Pharmacies
    • 4.1.2 Drug Stores
  • 4.2 Global Acute Migraine Drugs Sales Value by Application
    • 4.2.1 Global Acute Migraine Drugs Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Acute Migraine Drugs Sales Value, by Application (2020-2031)
    • 4.2.3 Global Acute Migraine Drugs Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Acute Migraine Drugs Sales Volume by Application
    • 4.3.1 Global Acute Migraine Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Acute Migraine Drugs Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Acute Migraine Drugs Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Acute Migraine Drugs Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Acute Migraine Drugs Sales Value by Region
    • 5.1.1 Global Acute Migraine Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Acute Migraine Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Acute Migraine Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Acute Migraine Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 Global Acute Migraine Drugs Sales Volume by Region
    • 5.2.1 Global Acute Migraine Drugs Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Acute Migraine Drugs Sales Volume by Region (2020-2025)
    • 5.2.3 Global Acute Migraine Drugs Sales Volume by Region (2026-2031)
    • 5.2.4 Global Acute Migraine Drugs Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Acute Migraine Drugs Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Acute Migraine Drugs Sales Value, 2020-2031
    • 5.4.2 North America Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Acute Migraine Drugs Sales Value, 2020-2031
    • 5.5.2 Europe Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Acute Migraine Drugs Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Acute Migraine Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Acute Migraine Drugs Sales Value, 2020-2031
    • 5.7.2 South America Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Acute Migraine Drugs Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Acute Migraine Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Acute Migraine Drugs Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Acute Migraine Drugs Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Acute Migraine Drugs Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Acute Migraine Drugs Sales Value, 2020-2031
    • 6.3.2 United States Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Acute Migraine Drugs Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Acute Migraine Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Acute Migraine Drugs Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Acute Migraine Drugs Sales Value, 2020-2031
    • 6.5.2 China Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Acute Migraine Drugs Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Acute Migraine Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Acute Migraine Drugs Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Acute Migraine Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Acute Migraine Drugs Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Acute Migraine Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Acute Migraine Drugs Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Acute Migraine Drugs Sales Value, 2020-2031
    • 6.9.2 India Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Acute Migraine Drugs Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 GSK
    • 7.1.1 GSK Company Information
    • 7.1.2 GSK Introduction and Business Overview
    • 7.1.3 GSK Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 GSK Acute Migraine Drugs Product Offerings
    • 7.1.5 GSK Recent Development
  • 7.2 Teva
    • 7.2.1 Teva Company Information
    • 7.2.2 Teva Introduction and Business Overview
    • 7.2.3 Teva Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Teva Acute Migraine Drugs Product Offerings
    • 7.2.5 Teva Recent Development
  • 7.3 Pfizer
    • 7.3.1 Pfizer Company Information
    • 7.3.2 Pfizer Introduction and Business Overview
    • 7.3.3 Pfizer Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Pfizer Acute Migraine Drugs Product Offerings
    • 7.3.5 Pfizer Recent Development
  • 7.4 Novartis
    • 7.4.1 Novartis Company Information
    • 7.4.2 Novartis Introduction and Business Overview
    • 7.4.3 Novartis Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Novartis Acute Migraine Drugs Product Offerings
    • 7.4.5 Novartis Recent Development
  • 7.5 Sun Pharma
    • 7.5.1 Sun Pharma Company Information
    • 7.5.2 Sun Pharma Introduction and Business Overview
    • 7.5.3 Sun Pharma Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Sun Pharma Acute Migraine Drugs Product Offerings
    • 7.5.5 Sun Pharma Recent Development
  • 7.6 Grunenthal
    • 7.6.1 Grunenthal Company Information
    • 7.6.2 Grunenthal Introduction and Business Overview
    • 7.6.3 Grunenthal Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Grunenthal Acute Migraine Drugs Product Offerings
    • 7.6.5 Grunenthal Recent Development
  • 7.7 Endo Pharmaceuticals
    • 7.7.1 Endo Pharmaceuticals Company Information
    • 7.7.2 Endo Pharmaceuticals Introduction and Business Overview
    • 7.7.3 Endo Pharmaceuticals Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Endo Pharmaceuticals Acute Migraine Drugs Product Offerings
    • 7.7.5 Endo Pharmaceuticals Recent Development
  • 7.8 Merck
    • 7.8.1 Merck Company Information
    • 7.8.2 Merck Introduction and Business Overview
    • 7.8.3 Merck Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Merck Acute Migraine Drugs Product Offerings
    • 7.8.5 Merck Recent Development
  • 7.9 J & J
    • 7.9.1 J & J Company Information
    • 7.9.2 J & J Introduction and Business Overview
    • 7.9.3 J & J Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 J & J Acute Migraine Drugs Product Offerings
    • 7.9.5 J & J Recent Development

8 Industry Chain Analysis

  • 8.1 Acute Migraine Drugs Industrial Chain
  • 8.2 Acute Migraine Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Acute Migraine Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Acute Migraine Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Acute Migraine Drugs Market Trends
  • Table 2. Acute Migraine Drugs Market Drivers & Opportunity
  • Table 3. Acute Migraine Drugs Market Challenges
  • Table 4. Acute Migraine Drugs Market Restraints
  • Table 5. Global Acute Migraine Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Acute Migraine Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Global Acute Migraine Drugs Sales Volume by Company (2020-2025) & (K Unit)
  • Table 8. Global Acute Migraine Drugs Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Acute Migraine Drugs Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Acute Migraine Drugs Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Acute Migraine Drugs Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Acute Migraine Drugs
  • Table 13. Global Acute Migraine Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Migraine Drugs as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Acute Migraine Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Acute Migraine Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Acute Migraine Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Acute Migraine Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Acute Migraine Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Acute Migraine Drugs Sales Volume by Type: 2020 VS 2024 VS 2031 (K Unit)
  • Table 22. Global Acute Migraine Drugs Sales Volume by Type (2020-2025) & (K Unit)
  • Table 23. Global Acute Migraine Drugs Sales Volume by Type (2026-2031) & (K Unit)
  • Table 24. Global Acute Migraine Drugs Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Acute Migraine Drugs Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Acute Migraine Drugs Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Acute Migraine Drugs Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Acute Migraine Drugs Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Acute Migraine Drugs Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Acute Migraine Drugs Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Acute Migraine Drugs Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Acute Migraine Drugs Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Acute Migraine Drugs Sales Volume by Application: 2020 VS 2024 VS 2031 (K Unit)
  • Table 34. Global Acute Migraine Drugs Sales Volume by Application (2020-2025) & (K Unit)
  • Table 35. Global Acute Migraine Drugs Sales Volume by Application (2026-2031) & (K Unit)
  • Table 36. Global Acute Migraine Drugs Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Acute Migraine Drugs Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Acute Migraine Drugs Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Acute Migraine Drugs Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Acute Migraine Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Acute Migraine Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Acute Migraine Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Acute Migraine Drugs Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Acute Migraine Drugs Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Acute Migraine Drugs Sales Volume by Region (K Unit): 2020 VS 2024 VS 2031
  • Table 46. Global Acute Migraine Drugs Sales Volume by Region (2020-2025) & (K Unit)
  • Table 47. Global Acute Migraine Drugs Sales Volume by Region (2026-2031) & (K Unit)
  • Table 48. Global Acute Migraine Drugs Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Acute Migraine Drugs Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Acute Migraine Drugs Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Acute Migraine Drugs Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Acute Migraine Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Acute Migraine Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Acute Migraine Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Acute Migraine Drugs Sales Volume, (2020-2025) & (K Unit)
  • Table 56. Key Countries/Regions Acute Migraine Drugs Sales Volume, (2026-2031) & (K Unit)
  • Table 57. GSK Company Information
  • Table 58. GSK Introduction and Business Overview
  • Table 59. GSK Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. GSK Acute Migraine Drugs Product Offerings
  • Table 61. GSK Recent Development
  • Table 62. Teva Company Information
  • Table 63. Teva Introduction and Business Overview
  • Table 64. Teva Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. Teva Acute Migraine Drugs Product Offerings
  • Table 66. Teva Recent Development
  • Table 67. Pfizer Company Information
  • Table 68. Pfizer Introduction and Business Overview
  • Table 69. Pfizer Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. Pfizer Acute Migraine Drugs Product Offerings
  • Table 71. Pfizer Recent Development
  • Table 72. Novartis Company Information
  • Table 73. Novartis Introduction and Business Overview
  • Table 74. Novartis Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Novartis Acute Migraine Drugs Product Offerings
  • Table 76. Novartis Recent Development
  • Table 77. Sun Pharma Company Information
  • Table 78. Sun Pharma Introduction and Business Overview
  • Table 79. Sun Pharma Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Sun Pharma Acute Migraine Drugs Product Offerings
  • Table 81. Sun Pharma Recent Development
  • Table 82. Grunenthal Company Information
  • Table 83. Grunenthal Introduction and Business Overview
  • Table 84. Grunenthal Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Grunenthal Acute Migraine Drugs Product Offerings
  • Table 86. Grunenthal Recent Development
  • Table 87. Endo Pharmaceuticals Company Information
  • Table 88. Endo Pharmaceuticals Introduction and Business Overview
  • Table 89. Endo Pharmaceuticals Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Endo Pharmaceuticals Acute Migraine Drugs Product Offerings
  • Table 91. Endo Pharmaceuticals Recent Development
  • Table 92. Merck Company Information
  • Table 93. Merck Introduction and Business Overview
  • Table 94. Merck Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Merck Acute Migraine Drugs Product Offerings
  • Table 96. Merck Recent Development
  • Table 97. J & J Company Information
  • Table 98. J & J Introduction and Business Overview
  • Table 99. J & J Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. J & J Acute Migraine Drugs Product Offerings
  • Table 101. J & J Recent Development
  • Table 102. Key Raw Materials Lists
  • Table 103. Raw Materials Key Suppliers Lists
  • Table 104. Acute Migraine Drugs Downstream Customers
  • Table 105. Acute Migraine Drugs Distributors List
  • Table 106. Research Programs/Design for This Report
  • Table 107. Key Data Information from Secondary Sources
  • Table 108. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Acute Migraine Drugs Product Picture
  • Figure 2. Global Acute Migraine Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Acute Migraine Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Acute Migraine Drugs Sales Volume (2020-2031) & (K Unit)
  • Figure 5. Global Acute Migraine Drugs Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Acute Migraine Drugs Report Years Considered
  • Figure 7. Global Acute Migraine Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Acute Migraine Drugs Players Sales Volume Ranking (2024) & (K Unit)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Acute Migraine Drugs Revenue in 2024
  • Figure 10. Acute Migraine Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Triptans Picture
  • Figure 12. NSAIDs Picture
  • Figure 13. Others Picture
  • Figure 14. Global Acute Migraine Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Acute Migraine Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Acute Migraine Drugs Sales Volume by Type (2020 VS 2024 VS 2031) & (K Unit)
  • Figure 17. Global Acute Migraine Drugs Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Acute Migraine Drugs Price by Type (2020-2031) & (USD/Unit)
  • Figure 19. Product Picture of Hospital Pharmacies
  • Figure 20. Product Picture of Drug Stores
  • Figure 21. Global Acute Migraine Drugs Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Acute Migraine Drugs Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. Global Acute Migraine Drugs Sales Volume by Application (2020 VS 2024 VS 2031) & (K Unit)
  • Figure 24. Global Acute Migraine Drugs Sales Volume Market Share by Application, 2024 & 2031
  • Figure 25. Global Acute Migraine Drugs Price by Application (2020-2031) & (USD/Unit)
  • Figure 26. North America Acute Migraine Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 27. North America Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Europe Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Europe Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Asia Pacific Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Asia Pacific Acute Migraine Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 32. South America Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. South America Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Middle East & Africa Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Middle East & Africa Acute Migraine Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Key Countries/Regions Acute Migraine Drugs Sales Value (%), (2020-2031)
  • Figure 37. Key Countries/Regions Acute Migraine Drugs Sales Volume (%), (2020-2031)
  • Figure 38. United States Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. United States Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 40. United States Acute Migraine Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Europe Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Europe Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Europe Acute Migraine Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 44. China Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. China Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 46. China Acute Migraine Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Japan Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Japan Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Japan Acute Migraine Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 50. South Korea Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. South Korea Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 52. South Korea Acute Migraine Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Southeast Asia Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Southeast Asia Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Southeast Asia Acute Migraine Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 56. India Acute Migraine Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. India Acute Migraine Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 58. India Acute Migraine Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Acute Migraine Drugs Industrial Chain
  • Figure 60. Acute Migraine Drugs Manufacturing Cost Structure
  • Figure 61. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed